Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Myasthenia Gravis.

Drachman DB.

Semin Neurol. 2016 Oct;36(5):419-424. Epub 2016 Sep 23. Review.

PMID:
27704496
2.

Comment: Methotrexate for patients with generalized myasthenia gravis.

Drachman DB.

Neurology. 2016 Jul 5;87(1):63. doi: 10.1212/WNL.0000000000002818. Epub 2016 Jun 15. No abstract available.

PMID:
27306630
3.

Treatment for Refractory Myasthenia Gravis-New Lymphs for Old.

Drachman DB.

JAMA Neurol. 2016 Jun 1;73(6):624-6. doi: 10.1001/jamaneurol.2016.0191. No abstract available.

PMID:
27044034
4.

Author response.

Drachman DB, Kaminski HJ.

Neurology. 2015 Jan 13;84(2):214. No abstract available.

PMID:
25729810
5.

A genome-wide association study of myasthenia gravis.

Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, Marangi G, Abramzon Y, Arepalli S, Chong S, Hernandez DG, Johnson JO, Bartoccioni E, Scuderi F, Maestri M, Gibbs JR, Errichiello E, ChiĆ² A, Restagno G, Sabatelli M, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel J, Freimer M, Kaminski HJ, Sanders DB, Lipscomb B, Massey JM, Chopra M, Howard JF Jr, Koopman WJ, Nicolle MW, Pascuzzi RM, Pestronk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqi Z, Muppidi S, Wolfe G, Richman D, Mezei MM, Jiwa T, Oger J, Drachman DB, Traynor BJ.

JAMA Neurol. 2015 Apr;72(4):396-404. doi: 10.1001/jamaneurol.2014.4103.

6.

Neuromuscular junction as Achilles' heel: yet another autoantibody?

Drachman DB, Kaminski HJ.

Neurology. 2014 Jun 3;82(22):1942-3. doi: 10.1212/WNL.0000000000000486. Epub 2014 May 2. No abstract available.

PMID:
24793186
7.

Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases.

Dezern AE, Styler MJ, Drachman DB, Hummers LK, Jones RJ, Brodsky RA.

Am J Blood Res. 2013;3(1):84-90. Epub 2013 Jan 17.

8.

Specific immunotherapy of experimental myasthenia gravis in vitro and in vivo: the Guided Missile strategy.

Sun W, Adams RN, Miagkov A, Lu Y, Juon HS, Drachman DB.

J Neuroimmunol. 2012 Oct 15;251(1-2):25-32. doi: 10.1016/j.jneuroim.2012.06.007. Epub 2012 Jul 5.

PMID:
22769060
9.

Strategy for treating motor neuron diseases using a fusion protein of botulinum toxin binding domain and streptavidin for viral vector access: work in progress.

Drachman DB, Adams RN, Balasubramanian U, Lu Y.

Toxins (Basel). 2010 Dec;2(12):2872-89. doi: 10.3390/toxins2122872. Epub 2010 Dec 20.

10.

High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.

DeZern AE, Petri M, Drachman DB, Kerr D, Hammond ER, Kowalski J, Tsai HL, Loeb DM, Anhalt G, Wigley F, Jones RJ, Brodsky RA.

Medicine (Baltimore). 2011 Mar;90(2):89-98. doi: 10.1097/MD.0b013e318210e685.

11.

Granzyme B: evidence for a role in the origin of myasthenia gravis.

Casciola-Rosen L, Miagkov A, Nagaraju K, Askin F, Jacobson L, Rosen A, Drachman DB.

J Neuroimmunol. 2008 Sep 15;201-202:33-40. doi: 10.1016/j.jneuroim.2008.04.041. Epub 2008 Aug 3.

12.

Therapy of myasthenia gravis.

Drachman DB.

Handb Clin Neurol. 2008;91:253-72. doi: 10.1016/S0072-9752(07)01508-4. Review. No abstract available.

PMID:
18631846
13.

Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.

Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA.

Ann N Y Acad Sci. 2008;1132:305-14. doi: 10.1196/annals.1405.033.

14.

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.

Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL, Richert ND, Pardo CA, Yousem DM, Hammond E, Quigg M, Trecker C, McArthur JC, Nath A, Greenberg BM, Calabresi PA, Kerr DA.

Arch Neurol. 2008 Aug;65(8):1044-51. doi: 10.1001/archneurol.65.8.noc80042. Epub 2008 Jun 9.

15.

Trial of celecoxib in amyotrophic lateral sclerosis.

Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, Drachman DB.

Ann Neurol. 2006 Jul;60(1):22-31.

PMID:
16802291
16.

Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design.

Schmidt EP, Drachman DB, Wiener CM, Clawson L, Kimball R, Lechtzin N.

Muscle Nerve. 2006 Jan;33(1):127-32.

PMID:
16258948
17.

Protection of human cerebral neurons from neurodegenerative insults by gene delivery of soluble tumor necrosis factor p75 receptor.

Williams MA, Turchan J, Lu Y, Nath A, Drachman DB.

Exp Brain Res. 2005 Sep;165(3):383-91. Epub 2005 Apr 13.

PMID:
15827736
18.

High-dose therapy for autoimmune neurologic diseases.

Drachman DB, Brodsky RA.

Curr Opin Oncol. 2005 Mar;17(2):83-8. Review.

PMID:
15725909
19.

Gene transfer of baculoviral p35 by adenoviral vector protects human cerebral neurons from apoptosis.

Miagkov A, Turchan J, Nath A, Drachman DB.

DNA Cell Biol. 2004 Aug;23(8):496-501.

PMID:
15307952
20.

Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients.

Zhou L, McConville J, Chaudhry V, Adams RN, Skolasky RL, Vincent A, Drachman DB.

Muscle Nerve. 2004 Jul;30(1):55-60.

PMID:
15221879
21.

Adventures in clinical and basic science.

Drachman DB.

J Hematother Stem Cell Res. 2003 Dec;12(6):595-601. No abstract available.

PMID:
14977469
22.

Specific immunotherapy of experimental myasthenia by genetically engineered APCs: the "guided missile" strategy.

Drachman DB, Wu JM, Miagkov A, Williams MA, Adams RN, Wu B.

Ann N Y Acad Sci. 2003 Sep;998:520-32.

PMID:
14592923
23.

Production and characterization of a T cell receptor transgenic mouse recognizing the immunodominant epitope of the Torpedo californica acetylcholine receptor.

Miagkov A, Lobito AA, Yang B, Lopes MF, Adams RN, Palardy GR, Johnson MM, McFarland H, Lenardo MJ, Drachman DB.

Ann N Y Acad Sci. 2003 Sep;998:379-83. No abstract available.

PMID:
14592900
24.

Autonomic "myasthenia": the case for an autoimmune pathogenesis.

Drachman DB.

J Clin Invest. 2003 Mar;111(6):797-9. No abstract available.

25.

Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide.

Drachman DB, Jones RJ, Brodsky RA.

Ann Neurol. 2003 Jan;53(1):29-34.

PMID:
12509845
26.

Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.

Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, Rothstein JD.

Ann Neurol. 2002 Dec;52(6):771-8.

PMID:
12447931
27.

T cell receptor transgenic mice recognizing the immunodominant epitope of the Torpedo californica acetylcholine receptor.

Lobito AA, Yang B, Lopes MF, Miagkov A, Adams RN, Palardy GR, Johnson MM, McFarland HI, Recher M, Drachman DB, Lenardo MJ.

Eur J Immunol. 2002 Jul;32(7):2055-67.

28.

Myasthenia gravis.

Vincent A, Drachman DB.

Adv Neurol. 2002;88:159-88. Review. No abstract available.

PMID:
11908224
29.

Specific immunotherapy of experimental myasthenia gravis in vitro: the "guided missile" strategy.

Wu JM, Wu B, Miagkov A, Adams RN, Drachman DB.

Cell Immunol. 2001 Mar 15;208(2):137-47.

PMID:
11333146
30.

Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy.

Wu B, Wu JM, Miagkov A, Adams RN, Levitsky HI, Drachman DB.

J Immunol. 2001 Apr 1;166(7):4773-9.

31.

Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.

Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB.

Neurology. 2001 Jan 9;56(1):94-6.

PMID:
11148242
32.
33.
34.

Targeting T cells in myasthenia gravis.

Drachman DB.

Ann Neurol. 1999 Oct;46(4):553-5. No abstract available.

PMID:
10514090
36.
37.

Factors that determine the severity of experimental myasthenia gravis.

Drachman DB, McIntosh KR, Yang B.

Ann N Y Acad Sci. 1998 May 13;841:262-82. Review.

PMID:
9668247
38.

How subtle differences in MHC class II affect the severity of experimental myasthenia gravis.

Yang B, McIntosh KR, Drachman DB.

Clin Immunol Immunopathol. 1998 Jan;86(1):45-58.

PMID:
9434796
39.

Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis.

Bulkley GB, Bass KN, Stephenson GR, Diener-West M, George S, Reilly PA, Baker RR, Drachman DB.

Ann Surg. 1997 Sep;226(3):324-34; discussion 334-5.

40.

Amyotrophic lateral sclerosis and antibodies to voltage-gated calcium channels--new doubts.

Vincent A, Drachman DB.

Ann Neurol. 1996 Nov;40(5):691-3. Review. No abstract available.

PMID:
8957007
41.

Immunotherapy in neuromuscular disorders: current and future strategies.

Drachman DB.

Muscle Nerve. 1996 Oct;19(10):1239-51. Review.

PMID:
8808649
42.

Partial T-cell receptor gene rearrangement. A source of pseudo-clonal populations in thymomas and other thymic tissues.

Pizer ES, McGrath SD, Hruban RH, Drachman DB, Bulkley GB, Zehnbauer BA.

Am J Clin Pathol. 1996 Mar;105(3):262-7.

PMID:
8602605
43.

Oral tolerance in myasthenia gravis.

Drachman DB, Okumura S, Adams RN, McIntosh KR.

Ann N Y Acad Sci. 1996 Feb 13;778:258-72. Review.

PMID:
8610979
45.

Internalization of IgG in motoneurons of patients with ALS: selective or nonselective?

Fishman PS, Drachman DB.

Neurology. 1995 Aug;45(8):1551-4.

PMID:
7543985
46.

Amyotrophic lateral sclerosis. An autoimmune disease?

Drachman DB, Fishman PS, Rothstein JD, Motomura M, Lang B, Vincent A, Mellits ED.

Adv Neurol. 1995;68:59-65. Review. No abstract available.

PMID:
8787243
47.

Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis.

Okumura S, McIntosh K, Drachman DB.

Ann Neurol. 1994 Nov;36(5):704-13.

PMID:
7979216
48.

Cholinergic stimulation of skeletal muscle cells induces rapid immediate early gene expression: role of intracellular calcium.

Abu-Shakra SR, Cole AJ, Adams RN, Drachman DB.

Brain Res Mol Brain Res. 1994 Oct;26(1-2):55-60.

PMID:
7854066
49.

Myasthenia gravis.

Drachman DB.

N Engl J Med. 1994 Jun 23;330(25):1797-810. Review. No abstract available.

PMID:
8190158
50.

Corneal decompensation in mitochondrial ophthalmoplegia plus (Kearns-Sayre) syndrome. A clinicopathologic case report.

Chang TS, Johns DR, Stark WJ, Drachman DB, Green WR.

Cornea. 1994 May;13(3):269-73.

PMID:
8033580

Supplemental Content

Loading ...
Support Center